[go: up one dir, main page]

AR035866A1 - 2- (REPLACED AMINO) -BENZOTIAZOL SULFONAMID SULFONAMID INHIBITORS OF SPECTRO HIV PROTEASE, A METHOD FOR THE PREPARATION, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM AND THE USE OF SUCH COMPOUNDS FOR THE MANUFACTURE OF MEDICINES - Google Patents

2- (REPLACED AMINO) -BENZOTIAZOL SULFONAMID SULFONAMID INHIBITORS OF SPECTRO HIV PROTEASE, A METHOD FOR THE PREPARATION, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM AND THE USE OF SUCH COMPOUNDS FOR THE MANUFACTURE OF MEDICINES

Info

Publication number
AR035866A1
AR035866A1 ARP020101491A AR035866A1 AR 035866 A1 AR035866 A1 AR 035866A1 AR P020101491 A ARP020101491 A AR P020101491A AR 035866 A1 AR035866 A1 AR 035866A1
Authority
AR
Argentina
Prior art keywords
alkyl
het1
het2
cycloalkyl
aryl
Prior art date
Application number
Other languages
Spanish (es)
Original Assignee
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tibotec Pharm Ltd filed Critical Tibotec Pharm Ltd
Priority to ARP020101491 priority Critical patent/AR035866A1/en
Publication of AR035866A1 publication Critical patent/AR035866A1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

2-(amino sustituido)-benzotiazol sulfonamidas, N-óxidos, sales, formas estereoisoméricas, mezclas racémicas, prodrogas, ésteres o metabolitos de los mismos, que comprende un compuesto de la fórmula (1), en donde R1 y R8 son, cada uno independientemente, hidrógeno, alquilo C1-6, alquenilo C2-6, arilalquilo C1-6, cicloalquilo C3-7, cicloalquil C3-7 alquilo C1-6, arilo, Het1, Het1-alquilo C1-6, Het2, o Het2-alquilo C1-6; R1 puede ser también un radical de fórmula (R11a)(R11b)NC(R10a)(R10b)CHR9- en la cual R9, R10a, R10b son, cada uno independientemente, hidrógeno, alquiloxicarbonilo C1-4, carboxilo, aminocarbonilo, mono- o di(alquil C1-4)aminocarbonilo, cicloalquilo C3-7, alquenilo C2-6, alquinilo C2-6, o alquilo C1-4 opcionalmente sustituido con arilo, Het1, Het2, cicloalquilo C3-7, alquiloxicarbonilo C1-4, carboxilo, aminocarbonilo, mono- o di(alquil C1-4)aminocarbonilo, aminosulfonilo, alquil C1-4S(O)t, hidroxi, ciano, halógeno o amino opcionalmente mono- o disustituido, donde los sustituyentes están seleccionados entre alquilo C1-4, arilo, arilalquilo C1-4, cicloalquilo C3-7, cicloalquil C3-7 alquilo C1-4, Het1, Het2, Het1-alquilo C1-4, Het2-alquilo C1-4; donde R9, R10a y los átomos de carbono a los cuales están adheridos pueden formar también un radical cicloalquilo C3-7; cuando L es -O-alcanodiilo C1-6-C(=O)- ó -NR8-alcanodiilo C1-6-C(=O)-, entonces R9 puede ser también oxo; R11a es hidrógeno, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-7, arilo, arilalquilo C1-4, aminocarbonilo opcionalmente mono- o disustituido, aminoalquilcarboniloxi C1-4 opcionalmente mono- o disustituido, alquiloxicarbonilo C1-4, ariloxicarbonilo, Het1-oxicarbonilo, Het2-oxicarbonilo, ariloxicarbonilalquilo C1-4, aril alquiloxicarbonilo, C1-4, alquilcarbonilo C1-4, cicloalquilcarbonilo C3-7, cicloalquil C3-7 alquiloxicarbonilo C1-4, cicloalquilcarboniloxi C3-7, carboxilo alquilcarboniloxi C1-4, alquilcarboniloxi C1-4, arilalquilcarboniloxi C1-4, arilcarboniloxi, ariloxicarboniloxi, Het1-carbonilo, Het1-carboniloxi, Het1-alquiloxicarbonilo C1-4, Het2-carboniloxi, Het2-alquilcarboniloxi C1-4, Het2-alquiloxicarboniloxi C1-4 o alquilo C1-4 opcionalmente sustituido con arilo, ariloxi, Het2, halógeno o hidroxi; donde los sustituyentes en los grupos amino están cada uno independientemente seleccionados entre alquilo C1-4, arilo, arilalquilo C1-4, cicloalquilo C3-7, cicloalquil C3-7 alquilo C1-4, Het1, Het2, Het1-alquilo C1-4 y Het2-alquilo C1-4; R11b es hidrógeno, cicloalquilo C3-7, alquenilo C2-6, alquinilo C2-6, arilo, alquil C1-6-oxicarbonilo, Het1, Het2 o alquilo C1-4 opcionalmente sustituido con halógeno, hidroxi, alquil C1-4 S(O)t, arilo, cicloalquilo C3-7, Het1, Het2, amino opcionalmente mono- o disustituido, donde los sustituyentes están seleccionados entre alquilo C1-4, arilo, arilalquilo C1-4, cicloalquilo C3-7, cicloalquil C3-7 alquilo C1-4, Het1, Het2, Het1-alquilo C1-4, Het2-alquilo C1-4; por lo cual R11 puede estar ligado al resto de la molécula a través de un grupo sulfonilo; cada t independientemente es cero, 1 ó 2; R2 es hidrógeno o alquilo C1-6; L es -C(=O)-, -O-C(=O)-, -NR8-C(O)-, -O-alcanodiilo C1-6-C(=O)-, -NR8-alcanodiilo C1-6-C(=O)-, -S(=O)2-, -NR8-S(=O)2 con lo cual cualquiera de los grupos C(=O) o el grupo S(=O)2 está adherido a la porción NR2; y por lo cual la porción alcanodiilo está opcionalmente sustituida con arilo, arilalquilo C1-4, cicloalquilo C3-7, cicloalquil C3-7 alquilo C1-4, Het1, Het2, Het1-alquilo C1-4 y Het2-alquilo C1-4; R3 es alquilo C1-6, arilo, cicloalquilo C3-7, cicloalquil C3-7 alquilo C1-4 o arilalquilo C1-4; R4 es hidrógeno, alquiloxicarbonilo C1-4, carboxilo, aminocarbonilo, mono- o di(alquil C1-4)aminocarbonilo, cicloalquilo C3-7, alquenilo C2-6, alquinilo C2-6 o alquilo C1-6 opcionalmente sustituido con arilo, Het1, Het2, cicloalquilo C3-7, alquiloxicarbonilo C1-4, carboxilo, aminocarbonilo, mono- o di(alquil C1-4) aminocarbonilo, aminosulfonilo, alquil C1-4 S(=O)t, hidroxi, ciano, halógeno, amino opcionalmente mono- o disustituido, ariloxicarbonilo donde los sustituyentes están seleccionados entre alquilo C1-4, arilo, arilalquilo C1-4, cicloalquilo C3-7, cicloalquil C3-7 alquilo C1-4, Het1, Het2, Het1-alquilo C1-4 y Het2-alquilo C1-4; A es alcanodiilo C1-6, -C(=O)-, -C(=S)-, -S(=O)2, alcanodiilo C1-6-C(=O)-, alcanodiilo C1-6-C(=S)- ó alcanodiilo C1-6-S(=O)2; donde el punto de adhesión al átomo de nitrógeno en el grupo alcanodiilo C1-6 en aquellas porciones contienen dicho grupo; R5 es hidrógeno, hidroxi, alquilo C1-6, Het1-alquilo C1-6, Het2-alquilo C1-6, aminoalquilo C1-6 donde el grupo amino puede estar opcionalmente mono- o disustituido con alquilo C1-4; R6 es alquiloxi C1-6, Het1, Het1-oxi, Het2, Het2-oxi, arilo, ariloxi o amino; y en caso de que -A- sea distinto de alcanodiilo C1-6, entonces R6 puede ser también alquilo C1-6, Het1-alquilo C1-4, Het1-oxialquilo C1-4, Het2-alquilo C1-4, Het2-oxialquilo C1-4, arilalquilo C1-4, ariloxialquilo C1-4, o aminoalquilo C1-4; por lo cual cada uno de los grupos amino en la definición de R6 puede estar opcionalmente sustituido con uno o más sustituyentes seleccionados entre el grupo alquilo C1-4, alquilcarbonilo C1-4 alquiloxicarbonilo C1-4, arilo, arilcarbonilo, ariloxicarbonilo, Het1, Het2, arilalquilo C1-4, Het1-alquilo C1-4 o Het2-alquilo C1-4; y R5 y -A-R6 es alquiloxi C1-6 tomados conjuntamente con el átomo de nitrógeno al cual están adheridos pueden formar también Het1 o Het2. Métodos para su preparación y composiciones farmacéuticas y uso de dichos compuestos para la manufactura de un medicamento como inhibidores de proteasa HIV, de amplio espectro.2- (substituted amino) -benzothiazole sulfonamides, N-oxides, salts, stereoisomeric forms, racemic mixtures, prodrugs, esters or metabolites thereof, comprising a compound of the formula (1), wherein R1 and R8 are, each one independently, hydrogen, C1-6 alkyl, C2-6 alkenyl, C1-6 arylalkyl, C3-7 cycloalkyl, C3-7 cycloalkyl C1-6 alkyl, aryl, Het1, Het1-C1-6 alkyl, Het2, or Het2- C1-6 alkyl; R1 may also be a radical of formula (R11a) (R11b) NC (R10a) (R10b) CHR9- in which R9, R10a, R10b are each independently hydrogen, C1-4 alkyloxycarbonyl, carboxyl, aminocarbonyl, mono- or di (C1-4 alkyl) aminocarbonyl, C3-7 cycloalkyl, C2-6 alkenyl, C2-6 alkynyl, or C1-4 alkyl optionally substituted with aryl, Het1, Het2, C3-7 cycloalkyl, C1-4 alkyloxycarbonyl, carboxyl , aminocarbonyl, mono- or di (C1-4 alkyl) aminocarbonyl, aminosulfonyl, C1-4S alkyl (O) t, hydroxy, cyano, halogen or optionally mono- or disubstituted amino, where the substituents are selected from C1-4 alkyl, aryl, C1-4 arylalkyl, C3-7 cycloalkyl, C3-7 cycloalkyl C1-4 alkyl, Het1, Het2, Het1-C1-4 alkyl, Het2-C1-4 alkyl; where R9, R10a and the carbon atoms to which they are attached can also form a C3-7 cycloalkyl radical; when L is -O-C1-6-C-alkanediyl (= O) - or -NR8-C1-6-C-alkanediyl (= O) -, then R9 can also be oxo; R11a is hydrogen, C2-6 alkenyl, C2-6 alkynyl, C3-7 cycloalkyl, aryl, C1-4 arylalkyl, optionally mono- or disubstituted aminocarbonyl, optionally mono- or disubstituted aminoalkylcarbonyloxyC 1-4 alkyl, aryloxycarbonyl, Het1-Oxycarbonyl, Het2-Oxycarbonyl, C 1-4 aryloxycarbonylalkyl, C 1-4 aryl alkoxycarbonyl, C 1-4 alkylcarbonyl, C 3-7 cycloalkylcarbonyl, C 3-7 alkyloxycarbonyl, C 1-4 alkylcarbonyloxy, C1-4 alkylcarbonyloxy, C1-4 arylalkylcarbonyloxy, arylcarbonyloxy, aryloxycarbonyloxy, Het1-carbonyl, Het1-carbonyloxy, Het1-C1-4 alkyloxycarbonyloxy, Het2-carbonyloxy, Het2-C1-4 alkylcarbonyloxy or C1-4alkyloxycarbonyloxy 4 optionally substituted with aryl, aryloxy, Het2, halogen or hydroxy; where the substituents in the amino groups are each independently selected from C1-4 alkyl, aryl, C1-4 arylalkyl, C3-7 cycloalkyl, C3-7 cycloalkyl C1-4 alkyl, Het1, Het2, Het1-C1-4 alkyl and Het2-C1-4 alkyl; R 11b is hydrogen, C 3-7 cycloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, aryl, C 1-6 alkyl-oxycarbonyl, Het 1, Het 2 or C 1-4 alkyl optionally substituted by halogen, hydroxy, C 1-4 alkyl (O ) t, aryl, C3-7 cycloalkyl, Het1, Het2, optionally mono- or disubstituted amino, where the substituents are selected from C1-4 alkyl, aryl, C1-4 arylalkyl, C3-7 cycloalkyl, C3-7 cycloalkyl C1 -4, Het1, Het2, Het1-C1-4 alkyl, Het2-C1-4 alkyl; whereby R11 can be linked to the rest of the molecule through a sulfonyl group; each t independently is zero, 1 or 2; R2 is hydrogen or C1-6 alkyl; L is -C (= O) -, -OC (= O) -, -NR8-C (O) -, -O-C1-6-C-alkanediyl (= O) -, -NR8-C1-6 alkanediyl- C (= O) -, -S (= O) 2-, -NR8-S (= O) 2 whereby any of the groups C (= O) or the group S (= O) 2 is attached to the NR2 portion; and whereby the alkanediyl portion is optionally substituted with aryl, C1-4 arylalkyl, C3-7 cycloalkyl, C3-7 cycloalkyl C1-4 alkyl, Het1, Het2, Het1-C1-4 alkyl and Het2-C1-4 alkyl; R3 is C1-6 alkyl, aryl, C3-7 cycloalkyl, C3-7 cycloalkyl C1-4 alkyl or C1-4 arylalkyl; R4 is hydrogen, C1-4 alkyloxycarbonyl, carboxyl, aminocarbonyl, mono- or di (C1-4 alkyl) aminocarbonyl, C3-7 cycloalkyl, C2-6 alkenyl, C2-6 alkynyl or C1-6 alkyl optionally substituted with aryl, Het1 , Het 2, C 3-7 cycloalkyl, C 1-4 alkyloxycarbonyl, carboxyl, aminocarbonyl, mono- or di (C 1-4 alkyl) aminocarbonyl, aminosulfonyl, C 1-4 alkyl (= O) t, hydroxy, cyano, halogen, amino optionally mono- or disubstituted, aryloxycarbonyl where the substituents are selected from C1-4 alkyl, aryl, C1-4 arylalkyl, C3-7 cycloalkyl, C3-7 cycloalkyl C1-4 alkyl, Het1, Het2, Het1-C1-4 alkyl and Het2 -C1-4 alkyl; A is C1-6 alkanediyl, -C (= O) -, -C (= S) -, -S (= O) 2, C1-6-C-alkanediyl (= O) -, C1-6-C alkanediyl ( = S) - or C1-6-S-alkanediyl (= O) 2; where the point of adhesion to the nitrogen atom in the C1-6 alkanediyl group in those portions contains said group; R5 is hydrogen, hydroxy, C1-6 alkyl, Het1-C1-6 alkyl, Het2-C1-6 alkyl, C1-6 aminoalkyl where the amino group may optionally be mono- or disubstituted with C1-4 alkyl; R6 is C1-6 alkyloxy, Het1, Het1-oxy, Het2, Het2-oxy, aryl, aryloxy or amino; and if -A- is different from C1-6 alkanediyl, then R6 can also be C1-6 alkyl, Het1-C1-4 alkyl, Het1-C1-4 oxyalkyl, Het2-C1-4 alkyl, Het2-oxyalkyl C1-4, C1-4 arylalkyl, C1-4 aryloxyalkyl, or C1-4 aminoalkyl; whereby each of the amino groups in the definition of R6 may be optionally substituted with one or more substituents selected from the group C1-4 alkyl, C1-4 alkylcarbonyl C1-4 alkyloxycarbonyl, aryl, arylcarbonyl, aryloxycarbonyl, Het1, Het2 , C1-4 arylalkyl, Het1-C1-4 alkyl or Het2-C1-4 alkyl; and R5 and -A-R6 is C1-6 alkyloxy taken together with the nitrogen atom to which they are attached can also form Het1 or Het2. Methods for its preparation and pharmaceutical compositions and use of said compounds for the manufacture of a medicament as a broad-spectrum HIV protease inhibitor.

ARP020101491 2002-04-24 2002-04-24 2- (REPLACED AMINO) -BENZOTIAZOL SULFONAMID SULFONAMID INHIBITORS OF SPECTRO HIV PROTEASE, A METHOD FOR THE PREPARATION, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM AND THE USE OF SUCH COMPOUNDS FOR THE MANUFACTURE OF MEDICINES AR035866A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ARP020101491 AR035866A1 (en) 2002-04-24 2002-04-24 2- (REPLACED AMINO) -BENZOTIAZOL SULFONAMID SULFONAMID INHIBITORS OF SPECTRO HIV PROTEASE, A METHOD FOR THE PREPARATION, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM AND THE USE OF SUCH COMPOUNDS FOR THE MANUFACTURE OF MEDICINES

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ARP020101491 AR035866A1 (en) 2002-04-24 2002-04-24 2- (REPLACED AMINO) -BENZOTIAZOL SULFONAMID SULFONAMID INHIBITORS OF SPECTRO HIV PROTEASE, A METHOD FOR THE PREPARATION, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM AND THE USE OF SUCH COMPOUNDS FOR THE MANUFACTURE OF MEDICINES

Publications (1)

Publication Number Publication Date
AR035866A1 true AR035866A1 (en) 2004-07-21

Family

ID=42632479

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020101491 AR035866A1 (en) 2002-04-24 2002-04-24 2- (REPLACED AMINO) -BENZOTIAZOL SULFONAMID SULFONAMID INHIBITORS OF SPECTRO HIV PROTEASE, A METHOD FOR THE PREPARATION, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM AND THE USE OF SUCH COMPOUNDS FOR THE MANUFACTURE OF MEDICINES

Country Status (1)

Country Link
AR (1) AR035866A1 (en)

Similar Documents

Publication Publication Date Title
AR084553A1 (en) HIDEROCICLIC INHIBITING IMIDAZOLIC DERIVATIVES OF b-SECRETASE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USE OF THE SAME TO TREAT NEURODEGENERATIVE DISEASES, IN PARTICULAR ALZHEIMER
AR119698A2 (en) AMIDE COMPOUND N-UREA SUBSTITUTED AMINO ACID DERIVED
AR073450A1 (en) DRUG COMBINATIONS UNDERSTANDING A DGAT INHIBITOR AND A PPAR AGONIST
AR035970A1 (en) 2-AMINO-BENZOXAZOL SULFONAMID SULFONAMID SPECTRUM OF HIV PROTEASE, PHARMACEUTICAL COMPOSITION, "IN VITRO" METHOD TO INHIBIT THE RETROVIRAL REPLICATION, AND USE OF THESE COMPOUNDS IN THE MANUFACTURE OF MEDICINAL MANUFACTURE
AR076435A1 (en) COMPOUNDS OF REPLACED INDAZOLS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND PROCESSES TO OBTAIN THEMSELVES
AR083367A1 (en) QUINAZOLINONE TYPE COMPOUNDS AS CRTH ANTAGONISTS
AR038240A1 (en) PIPERIDINE COMPOUND, USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND PROCEDURE FOR PREPARATION
AR062677A1 (en) DERIVATIVES OF BIARIL-SULFONAMIDE, PRODUCTION PROCESSES AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM
AR087711A1 (en) INHIBITORS OF QUINURENINA-3-MONOOXIGENASA, PHARMACEUTICAL COMPOSITIONS AND USE OF THEM FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS
CO5640152A2 (en) PHARMACEUTICAL COMPOSITIONS FOR INHIBITORS OF THE PROTEASE OF THE VIRUS OF HEPATITIS C
AR100438A1 (en) PIRAZOLOPIRIDINAS AND PIRAZOLOPIRIMIDINAS
AR069510A1 (en) ARILO AND HETEROARILO IMIDAZO [1,5-A] FUSIONED PIRAZINS AS INHIBITORS OF PHOSPHODIESTERASE 10
AR100806A1 (en) 3-QUINASA PHOSFATIDYLINOSITOL INHIBITORS
AR066154A1 (en) PIPERIDINE / PIPERAZINE DERIVATIVES
AR100810A1 (en) 3-QUINASA PHOSFATIDYLINOSITOL INHIBITORS
AR088218A1 (en) USEFUL HETEROCICLICAL COMPOUNDS AS PI3K INHIBITORS
CY1108073T1 (en) INHIBITORS OF HIV SULFONAMIDIUM SPECTROLINE PROTECTION 2- (Substituted-amino) benzothiothiazole
AR046600A1 (en) DIAZAESPIROALCANOS AND ITS USE AS A TREATMENT FOR DISEASES MEDIATED BY CCR8
AR086977A1 (en) USEFUL NITROGEN HETEROCICLIC DERIVATIVES FOR THE TREATMENT OF CANCER AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
AR087760A1 (en) HETEROCICLILAMINAS AS PI3K INHIBITORS
PE20142081A1 (en) QUINURENIN-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE OF THEM
AR078164A1 (en) ISOXAZOLIDINE DERIVATIVES, PROCESS TO PREPARE SUCH COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM
AR044518A1 (en) HIV INTEGRAS INHIBITORS
AR085817A1 (en) ISOXAZOLIDINE DERIVATIVES
AR061185A1 (en) HETEROCICLICAL COMPOUNDS AS INHIBITORS OF HSP90. PHARMACEUTICAL COMPOSITIONS.

Legal Events

Date Code Title Description
FG Grant; registration